Dr. Harrison W. Farber, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- George Washington University School of Medicine (1977)
- Years since graduation
- 49
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 283
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1977Medical school: George Washington University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
MA license 47862 -
Internal Medicine Physician
MA license 47862
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Tufts Medical Center Boston, MA
- Lowell General Hospital Lowell, MA
Medical groups
- Pratt Medical Group Inc (286 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 283
- Services billed
- 985
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 233 | 109 |
| Critical care, first 30-74 minutes | 109 | 39 |
| Telephone medical discussion with physician, 21-30 minutes | 105 | 52 |
| Insertion of tube in right heart chambers for measurement | 77 | 73 |
| New patient office or other outpatient visit, 45-59 minutes | 62 | 62 |
| Established patient office or other outpatient visit, 20-29 minutes | 53 | 34 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 25 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tadalafil | 328 |
| Ambrisentan | 322 |
| Adempas (riociguat) | 130 |
| Opsumit (macitentan) | 128 |
| Furosemide Other prescribers in Boston, MA | 126 |
| Uptravi (selexipag) | 115 |
| Sildenafil Citrate Other prescribers in Boston, MA | 73 |
| Tyvaso Dpi (treprostinil) | 72 |
| Winrevair (sotatercept-csrk) | 68 |
| Opsynvi (macitentan/tadalafil) | 68 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 86 payments worth $19,466 in total to this clinician.
| Merck Sharp & Dohme LLC | $7,726 |
|---|---|
| Actelion Pharmaceuticals US, Inc. | $4,261 |
| United Therapeutics Corporation | $3,669 |
| Alphatec Spine, Inc | $1,285 |
| Globus Medical, Inc. | $837 |
| Zoll Medical Corporation | $265 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $207 |
| Genzyme Corporation | $198 |
| Consulting Fee | $12,533 |
|---|---|
| Food and Beverage | $3,557 |
| Travel and Lodging | $3,377 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Jul 1, 2025 | Consulting Fee | $5,760 |
| Actelion Pharmaceuticals US, Inc. Nov 11, 2025 | Consulting Fee UPTRAVI · Cardiology | $3,988 |
| United Therapeutics Corporation Oct 18, 2025 | Consulting Fee | $2,520 |
| Merck Sharp & Dohme LLC Jun 19, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Philadelphia, PA · in-kind | $988 |
| Alphatec Spine, Inc Apr 10, 2025 | Travel and Lodging Other - Miscellaneous · Orthopedics/Orthopedic Surgery · travel to Carlsbad, CA Company’s descriptionMAR 6-8,2025: ROOM CHARGE AT MISSION PACIFIC HOTEL | $901 |
| Alphatec Spine, Inc Apr 10, 2025 | Travel and Lodging Other - Miscellaneous · Orthopedics/Orthopedic Surgery · travel to CARLSBAD, CA · in-kind | $384 |
| Merck Sharp & Dohme LLC Jun 19, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Philadelphia, PA · in-kind | $272 |
| Zoll Medical Corporation Dec 18, 2025 | Consulting Fee Defibrillator · Resuscitation | $265 |
| Globus Medical, Inc. Jan 15, 2025 | Travel and Lodging EXCELSIUS GPS · SPINE/SPINE SURGERY · travel to King of Prussia, PA | $264 |
| Merck Sharp & Dohme LLC Jun 20, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Philadelphia, PA · in-kind | $249 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Zoll Medical Corporation Dec 18, 2025 | Consulting Fee Defibrillator · Resuscitation | $265 |
| Actelion Pharmaceuticals US, Inc. Nov 11, 2025 | Consulting Fee UPTRAVI · Cardiology | $3,988 |
| United Therapeutics Corporation Oct 18, 2025 | Consulting Fee | $2,520 |
| Merck Sharp & Dohme LLC Jul 1, 2025 | Consulting Fee | $5,760 |
| Merck Sharp & Dohme LLC Jul 1, 2025 | Travel and Lodging travel to Philadelphia, PA | $150 |
| Merck Sharp & Dohme LLC Jun 20, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Philadelphia, PA · in-kind | $249 |
| Merck Sharp & Dohme LLC Jun 19, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Philadelphia, PA · in-kind | $988 |
| Merck Sharp & Dohme LLC Jun 19, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Philadelphia, PA · in-kind | $272 |
| Alphatec Spine, Inc Apr 10, 2025 | Travel and Lodging Other - Miscellaneous · Orthopedics/Orthopedic Surgery · travel to Carlsbad, CA Company’s descriptionMAR 6-8,2025: ROOM CHARGE AT MISSION PACIFIC HOTEL | $901 |
| Alphatec Spine, Inc Apr 10, 2025 | Travel and Lodging Other - Miscellaneous · Orthopedics/Orthopedic Surgery · travel to CARLSBAD, CA · in-kind | $384 |
| Globus Medical, Inc. Jan 15, 2025 | Travel and Lodging EXCELSIUS GPS · SPINE/SPINE SURGERY · travel to King of Prussia, PA | $264 |
| Globus Medical, Inc. Jan 14, 2025 | Travel and Lodging EXCELSIUS GPS · SPINE/SPINE SURGERY · travel to King of Prussia, PA | $169 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 1 companies. The companies reported $254,701 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Hea…
Merck Sharp & Dohme LLC - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension PAH World Health Organizati…
Merck Sharp & Dohme LLC - An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH MK-7962-038
Merck Sharp & Dohme LLC - An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.